ReviewCurrent rheumatology reports2021
Into Clinical Practice: Diagnosis and Therapy of Retroperitoneal Fibrosis.
Review in Current rheumatology reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 32 citations in OpenAlex.
- IgG4-Related Kidney Disease and IgG4-Related Retroperitoneal Fibrosis: An Update on Diagnosis and Treatment.Kidney international reports · 2026Review
- Article
- Clinical features, diagnosis, and management of retroperitoneal fibrosis in a university referral hospital and literature review.Internal and emergency medicine · 2026Review
- Comparable effectiveness of intensive intravenous and less intensive immunosuppressive treatment in retroperitoneal fibrosis: a retrospective real-world cohort study.Rheumatology international · 2026Observational
- Pharmacological treatment of idiopathic retroperitoneal fibrosis.Reumatologia · 2026Review
- ARID1A-Deficient and 11q13-Amplified Metastatic Pancreatic Cancer Initially Presenting as Retroperitoneal Fibrosis in a Patient with Familial CHEK2 Variant.Diagnostics (Basel, Switzerland) · 2025Article
- Clinical characterization of aortitis and periaortitis: study of 134 patients from a single university hospital.Internal and emergency medicine · 2025Observational
- A review of the current treatment methods for retroperitoneal fibrosis with obstructive uropathy.BJUI compass · 2024Review
- Diagnostic value of contrast-enhanced ultrasound in the activity of idiopathic retroperitoneal fibrosis: a retrospective study.Clinical rheumatology · 2024Article
- The Onset of IgG4-related Retroperitoneal Fibrosis under Administration of a TNF Inhibitor in a Rheumatoid Arthritis Patient.Internal medicine (Tokyo, Japan) · 2023Article
- End-stage renal disease due to retroperitoneal fibrosis in neurofibromatosis type I.Intractable & rare diseases research · 2023Article
- Spectrum of Large and Medium Vessel Vasculitis in Adults: Primary Vasculitides, Arthritides, Connective Tissue, and Fibroinflammatory Diseases.Current rheumatology reports · 2022Review
- Idiopathic retroperitoneal fibrosis with endometrial cancer: a case report and literature review.BMC women's health · 2022Review
- Case Report: A Programmed Cell Death-1 Inhibitor-Related Abdominal Fibroinflammatory Reaction Affecting Multiple Organs in A Non-Small-Cell Lung Cancer Patient.Frontiers in immunology · 2022Article
- A case of idiopathic retroperitoneal fibrosis presenting as gallbladder carcinoma.BMC surgery · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of the reviewWe aim to review the most relevant diagnostic features and treatment options of retroperitoneal fibrosis, in order to provide a useful guide for clinical practice. RECENT
findingsThe recent literature highlights the role of imaging studies such as computed tomography, magnetic resonance imaging and positron emission tomography as useful tools for the diagnosis of retroperitoneal fibrosis, with retroperitoneal biopsy being reserved to atypical cases. The treatment approach is mainly conservative and is based on the use of medical therapies plus urological interventions. Medical therapies essentially comprise glucocorticoids and immunosuppressants-either traditional or biological agents such as rituximab. Surgical ureterolysis is only left for refractory cases. Recent findings in retroperitoneal fibrosis highlight the possibility of a non-invasive diagnostic approach and a conservative treatment strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.